CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
40.00
0%
Market Trading Hours* (UTC) Opens on Thursday at 07:00

Mon - Fri: 07:00 - 15:20

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 1.35
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.015699 %
Charges from full value of position ($-2.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.015699%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.006523 %
Charges from full value of position ($-1.24)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.006523%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency CHF
Margin 5%
Stock exchange Switzerland
Commission on trade 0%

*Information provided by Capital.com

Basilea Pharmaceutica AG Allschwil ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 40
Open* 40.05
1-Year Change* -2.55%
Day's Range* 40 - 40.75
52 wk Range 36.80-55.40
Average Volume (10 days) 20.90K
Average Volume (3 months) 502.88K
Market Cap 619.62M
P/E Ratio 10.05
Shares Outstanding 11.98M
Revenue 174.02M
EPS 4.71
Dividend (Yield %) N/A
Beta 1.26
Next Earnings Date Feb 12, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Oct 3, 2023 40.00 -1.40 -3.38% 41.40 41.80 40.00
Oct 2, 2023 41.65 -0.05 -0.12% 41.70 42.25 41.10
Sep 29, 2023 40.00 -0.65 -1.60% 40.65 41.55 40.00
Sep 28, 2023 40.80 -0.55 -1.33% 41.35 41.40 40.40
Sep 27, 2023 40.95 0.80 1.99% 40.15 41.10 40.15
Sep 26, 2023 40.45 -1.25 -3.00% 41.70 41.90 40.45
Sep 25, 2023 41.45 -0.80 -1.89% 42.25 42.50 41.15
Sep 22, 2023 42.40 0.20 0.47% 42.20 42.95 42.15
Sep 21, 2023 42.80 -0.15 -0.35% 42.95 43.60 42.75
Sep 20, 2023 43.40 -0.05 -0.12% 43.45 43.65 42.90
Sep 19, 2023 43.15 -0.45 -1.03% 43.60 44.75 43.15
Sep 18, 2023 43.80 -1.10 -2.45% 44.90 44.95 43.45
Sep 15, 2023 45.15 -0.20 -0.44% 45.35 45.65 44.60
Sep 14, 2023 44.80 -1.45 -3.14% 46.25 46.85 44.80
Sep 13, 2023 46.05 1.00 2.22% 45.05 47.55 44.70
Sep 12, 2023 47.45 0.60 1.28% 46.85 47.65 46.45
Sep 11, 2023 46.90 -0.25 -0.53% 47.15 48.30 46.90
Sep 8, 2023 47.85 0.90 1.92% 46.95 48.00 46.70
Sep 7, 2023 46.35 0.05 0.11% 46.30 47.20 46.30
Sep 6, 2023 47.25 0.85 1.83% 46.40 47.30 45.75

Basilea Pharma AG Events

Time (UTC) Country Event
Monday, February 12, 2024

Time (UTC)

07:30

Country

CH

Event

Full Year 2023 Basilea Pharmaceutica AG Earnings Release
Full Year 2023 Basilea Pharmaceutica AG Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 147.765 148.122 127.629 134.381 132.555
Revenue 147.765 148.122 127.629 134.381 132.555
Cost of Revenue, Total 24.603 24.072 24.054 18.868 20.299
Gross Profit 123.162 124.05 103.575 115.513 112.256
Total Operating Expense 129.263 147.432 136.165 151.581 156.65
Selling/General/Admin. Expenses, Total 30.815 29.721 29.422 30.051 31.409
Research & Development 73.804 93.157 97.41 102.662 104.942
Operating Income 18.502 0.69 -8.536 -17.2 -24.095
Interest Income (Expense), Net Non-Operating -9.522 -8.085 -7.485 -6.396 -6.528
Other, Net 3.122 0.601 1.354 1.214 -0.537
Net Income Before Taxes 12.102 -6.794 -14.667 -22.382 -31.16
Net Income After Taxes 12.147 -6.831 -14.722 -22.422 -31.352
Net Income Before Extra. Items 12.147 -6.831 -14.722 -22.422 -31.352
Net Income 12.147 -6.831 -14.722 -22.422 -31.352
Income Available to Common Excl. Extra. Items 12.147 -6.831 -14.722 -22.422 -31.352
Income Available to Common Incl. Extra. Items 12.147 -6.831 -14.722 -22.422 -31.352
Diluted Net Income 12.147 -6.831 -14.722 -22.422 -31.352
Diluted Weighted Average Shares 11.861 11.682 10.2815 10.7557 10.8379
Diluted EPS Excluding Extraordinary Items 1.02412 -0.58475 -1.43189 -2.08466 -2.89281
Dividends per Share - Common Stock Primary Issue 0 0 0 0 0
Diluted Normalized EPS 1.02636 -0.55793 -2.36256 -2.08466 -2.89281
Unusual Expense (Income) 0.041 0.482 -14.721
Other Operating Expenses, Total 0
Jun 2023 Dec 2022 Jun 2022 Dec 2021 Jun 2021
Total revenue 84.905 89.118 57.647 93.924 54.198
Revenue 84.905 89.118 57.647 93.924 54.198
Cost of Revenue, Total 9.996 9.684 14.919 10.547 13.525
Gross Profit 74.909 79.434 42.728 83.377 40.673
Total Operating Expense 48.007 61.531 67.732 77.624 69.808
Selling/General/Admin. Expenses, Total 16.544 15.194 15.621 15.382 14.339
Research & Development 21.467 36.656 37.148 51.468 41.689
Operating Income 36.898 27.587 -10.085 16.3 -15.61
Interest Income (Expense), Net Non-Operating -5.307 -5.773 -3.749 -4.01 -4.075
Other, Net 0.276 2.509 1.613 0.793 -0.192
Net Income Before Taxes 31.867 24.323 -12.221 13.083 -19.877
Net Income After Taxes 31.84 24.356 -12.209 13.06 -19.891
Net Income Before Extra. Items 31.84 24.356 -12.209 13.06 -19.891
Net Income 31.84 24.356 -12.209 13.06 -19.891
Income Available to Common Excl. Extra. Items 31.84 24.356 -12.209 13.06 -19.891
Income Available to Common Incl. Extra. Items 31.84 24.356 -12.209 13.06 -19.891
Diluted Net Income 31.84 24.356 -12.209 13.06 -19.891
Diluted Weighted Average Shares 11.9781 11.8828 11.8391 11.7986 11.5653
Diluted EPS Excluding Extraordinary Items 2.65818 2.04969 -1.03124 1.10691 -1.71988
Dividends per Share - Common Stock Primary Issue 0 0 0 0 0
Diluted Normalized EPS 2.65818 2.04952 -1.02883 1.12612 -1.70555
Unusual Expense (Income) 0 -0.003 0.044 0.227 0.255
Other Operating Expenses, Total 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 175.364 241.066 223.528 184.86 274.738
Cash and Short Term Investments 84.659 148.7 161.772 129.024 223.034
Cash 34.7 53.7 50.1 52.5 37.4
Cash & Equivalents 49.959 0 10.649 56.524 135.634
Short Term Investments 0 95 101.023 20 50
Total Receivables, Net 63.612 65.7 37.901 30.315 35.593
Accounts Receivable - Trade, Net 33.152 8.71 6.242 3.757
Total Inventory 24.244 22.783 21.192 18.569 14.411
Other Current Assets, Total 2.849 3.883 2.663 6.952 1.7
Total Assets 220.848 247.267 229.794 221.467 281.751
Property/Plant/Equipment, Total - Net 21.571 2.923 5.275 5.162 6.424
Property/Plant/Equipment, Total - Gross 30.294 17.505 29.348 44.2 45
Accumulated Depreciation, Total -10.3 -14.6 -24.1 -39 -38.6
Intangibles, Net 0.578 0.632 0.672 0.372 0.372
Long Term Investments 0 30 0
Other Long Term Assets, Total 22.069 0.256 0.319 1.073 0.217
Total Current Liabilities 74.85 174.408 50.161 75.494 66.684
Accounts Payable 0.191 10.617 13.151 6.765 6.399
Accrued Expenses 27.859 33.453 29.052 29.3 26.7
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 9.333 6.833 7.958 39.429 33.585
Total Liabilities 241.563 305.874 331.84 314.427 348.438
Total Long Term Debt 131.36 94.544 239.668 197.74 196.982
Long Term Debt 131.36 94.544 239.668 197.74 196.982
Other Liabilities, Total 35.353 36.922 42.011 41.193 84.772
Total Equity -20.715 -58.607 -102.046 -92.96 -66.687
Common Stock 13.093 12.992 11.922 11.882 11.879
Retained Earnings (Accumulated Deficit) 26.048 6.577 -33.95 -74.324 -55.05
Treasury Stock - Common -56.071 -56.559 -52.766 -5.963 -7.235
Other Equity, Total -3.785 -21.617 -27.252 -24.555 -16.281
Total Liabilities & Shareholders’ Equity 220.848 247.267 229.794 221.467 281.751
Total Common Shares Outstanding 11.9513 11.842 10.8673 10.7739 10.7447
Note Receivable - Long Term 1.266 2.39
Current Port. of LT Debt/Capital Leases 37.467 123.505
Dec 2022 Jun 2022 Dec 2021 Jun 2021 Dec 2020
Total Current Assets 175.364 211.789 241.066 220.189 223.528
Cash and Short Term Investments 84.659 140.736 148.7 162.849 161.772
Cash & Equivalents 84.659 45.746 53.7 82.849 60.749
Short Term Investments 0 94.99 95 80 101.023
Total Receivables, Net 63.612 39.72 65.7 31.264 37.901
Accounts Receivable - Trade, Net 33.152 10.946 6.618 8.71
Total Inventory 24.244 24.754 22.783 20.94 21.192
Other Current Assets, Total 2.849 6.579 3.883 5.136 2.663
Total Assets 220.848 236.073 247.267 227.176 229.794
Property/Plant/Equipment, Total - Net 21.571 21.619 2.923 3.767 5.275
Property/Plant/Equipment, Total - Gross 30.294 36.044 17.505 20.772 29.348
Accumulated Depreciation, Total -10.3 -14.4 -14.6 -17 -24.1
Intangibles, Net 0.578 1.247 0.632 0.467 0.672
Long Term Investments 0
Other Long Term Assets, Total 22.069 0.152 0.256 0.363 0.319
Total Current Liabilities 74.85 155.443 174.408 37.707 50.161
Accounts Payable 0.191 4.706 10.617 5.378 13.151
Accrued Expenses 27.859 23.709 33.453 25.235 29.052
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 9.333 9.833 6.833 7.094 7.958
Total Liabilities 241.563 303.239 305.874 305.928 331.84
Total Long Term Debt 131.36 94.77 94.544 227.869 239.668
Long Term Debt 131.36 94.77 94.544 227.869 239.668
Other Liabilities, Total 35.353 53.026 36.922 40.352 42.011
Total Equity -20.715 -67.166 -58.607 -78.752 -102.046
Common Stock 13.093 12.999 12.992 12.931 11.922
Retained Earnings (Accumulated Deficit) 26.048 -3.794 6.577 -10.401 -33.95
Treasury Stock - Common -56.071 -55.865 -56.559 -56.309 -52.766
Other Equity, Total -3.785 -20.506 -21.617 -24.973 -27.252
Total Liabilities & Shareholders’ Equity 220.848 236.073 247.267 227.176 229.794
Total Common Shares Outstanding 11.9513 11.8512 11.842 11.7932 10.8673
Current Port. of LT Debt/Capital Leases 37.467 117.195 123.505
Note Receivable - Long Term 1.266 1.266 2.39 2.39
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 12.147 -6.831 -14.722 -22.422 -31.352
Cash From Operating Activities 7.056 -32.02 -54.134 -63.836 -79.21
Cash From Operating Activities 1.097 0.754 1.19 1.639 1.852
Non-Cash Items 4.095 5.844 -9.84 3.806 7.009
Changes in Working Capital -10.283 -31.787 -30.762 -46.859 -56.719
Cash From Investing Activities 91.649 3.575 -34.963 -0.404 59.391
Capital Expenditures -3.303 -0.86 -2.265 -0.404 -0.609
Other Investing Cash Flow Items, Total 94.952 4.435 -32.698 0 60
Cash From Financing Activities -45.246 16.64 45.067 1.309 -5.986
Issuance (Retirement) of Stock, Net 4.426 39.852 4.809 1.309 -5.986
Issuance (Retirement) of Debt, Net -49.672 -23.212 43.451
Foreign Exchange Effects 0.155 0.501 -0.758 0.067 -1.011
Net Change in Cash 53.614 -11.304 -44.788 -62.864 -26.816
Cash Taxes Paid 0.004 0.035 0.026 0.141 0.413
Cash Interest Paid 6.334 7.074 4.843 5.666 5.795
Financing Cash Flow Items -3.193
Dec 2022 Jun 2022 Dec 2021 Jun 2021 Dec 2020
Net income/Starting Line 12.147 -12.209 -6.831 -19.891 -14.722
Cash From Operating Activities 7.056 0.149 -32.02 -27.151 -54.134
Cash From Operating Activities 1.097 0.357 0.754 0.399 1.19
Non-Cash Items 4.095 2.36 5.844 2.705 -9.84
Changes in Working Capital -10.283 9.641 -31.787 -10.364 -30.762
Cash From Investing Activities 91.649 -2.319 3.575 19.113 -34.963
Capital Expenditures -3.303 -2.329 -0.86 -0.307 -2.265
Other Investing Cash Flow Items, Total 94.952 0.01 4.435 19.42 -32.698
Cash From Financing Activities -45.246 -6.764 16.64 26.195 45.067
Issuance (Retirement) of Stock, Net 4.426 -0.165 39.852 38.82 4.809
Foreign Exchange Effects 0.155 0.841 0.501 0.249 -0.758
Net Change in Cash 53.614 -8.093 -11.304 18.406 -44.788
Financing Cash Flow Items -3.193
Issuance (Retirement) of Debt, Net -49.672 -6.599 -23.212 -12.625 43.451
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Black Creek Investment Management, Inc. Investment Advisor 5.0663 663670 25430 2023-05-08 LOW
CI Global Asset Management Investment Advisor/Hedge Fund 4.8722 638240 4613 2022-12-31 MED
Credit Suisse Asset Management Investment Advisor/Hedge Fund 3.2548 426360 -369 2022-12-31 LOW
Family (Braginsky) Other Insider Investor 3.0067 393863 5928 2022-12-31 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.7043 354254 2358 2023-07-31 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 2.4333 318750 153618 2022-11-29 LOW
Zürcher Kantonalbank (Asset Management) Bank and Trust 2.4288 318169 -13081 2023-06-30 LOW
ACATIS Investment Kapitalverwaltungsgesellschaft GmbH Investment Advisor 2.3711 310600 0 2023-06-30 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 2.0768 272047 272047 2022-12-31 LOW
UBS Asset Management (Switzerland) Investment Advisor 1.0368 135818 -1154 2023-07-31 LOW
JPMorgan Chase & Co Holding Company 1.0318 135155 -267417 2023-03-22 HIGH
JPMorgan Asset Management U.K. Limited Investment Advisor/Hedge Fund 0.8234 107866 0 2023-07-31 LOW
Saint Olive Gestion Investment Advisor 0.5344 70000 0 2022-12-31 LOW
Bank J. Safra Sarasin AG (Asset Management) Bank and Trust 0.515 67464 -5901 2023-06-30 MED
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 0.4538 59446 0 2023-07-31 LOW
California State Teachers Retirement System Pension Fund 0.3755 49183 723 2022-06-30 LOW
Baillie Gifford & Co. Investment Advisor 0.2626 34404 1018 2023-04-30 LOW
Deka Investment GmbH Investment Advisor/Hedge Fund 0.2523 33056 -3500 2022-12-31 LOW
Pictet Asset Management Ltd. Investment Advisor/Hedge Fund 0.2484 32542 0 2023-04-30 LOW
BlackRock Advisors (UK) Limited Investment Advisor/Hedge Fund 0.2322 30417 190 2023-07-31 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Basilea Company profile

About Basilea Pharmaceutica AG

Basilea Pharmaceutica AG is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development and commercialization of innovative pharmaceutical products to meet the needs of patients with cancer and infectious diseases. It launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. Additionally It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in its portfolio.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Basilea Pharmaceutica AG revenues increased 16% to SF148.1M. Net loss decreased 54% to SF6.8M. Revenues reflect Japan segment increase of 41% to SF56.5M, Republic of Ireland segment increase of 9% to SF62.1M. Lower net loss reflects Research & development expenses, net - B decrease of 4% to SF91.6M (expense), Stock-based Compensation in SGA decrease of 6% to SF1.7M (expense).

Industry: Biotechnology & Medical Research (NEC)

Hegenheimermattweg 167b
ALLSCHWIL
BASEL-LANDSCHAFT 4123
CH

Income Statement

  • Annual
  • Quarterly

News

How to Trade The Triple Top

Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.

14:13, 27 September 2023
USA flag on the background of stock charts. Financial system in USA

Q4 lookahead: US indices starting to show signs of trouble?

US indices start to draw attention as traders focus on the outlook for Q4.

07:20, 27 September 2023

USD/JPY Climbs Towards Key Highs

USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

11:32, 26 September 2023

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

People also watch

XRP/USD

0.54 Price
+2.590% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

US100

14,794.20 Price
+1.590% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 21:00 (UTC)
Spread 1.8

BTC/USD

27,651.25 Price
+0.590% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

Gold

1,822.27 Price
-0.040% 1D Chg, %
Long position overnight fee -0.0092%
Short position overnight fee 0.0010%
Overnight fee time 21:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading